Eli Lilly and Co
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors
- Conditions
- MalignancyMetastasis
- Interventions
- Biological: Olaratumab
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT01199822
- Locations
- π―π΅
ImClone Investigational Site, Kashiwa, Chiba, Japan
A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1041
- Registration Number
- NCT01198002
- Locations
- πΊπ¦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
- Conditions
- Connective Tissue DiseaseAutoimmune DiseaseSystemic Lupus Erythematosus
- Interventions
- Drug: LY2127399Drug: Placebo every 2 weeksDrug: Placebo every 4 weeksDrug: Standard of Care
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1164
- Registration Number
- NCT01196091
- Locations
- πΊπ¦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zhytomyr, Ukraine
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 884
- Registration Number
- NCT01191268
- Locations
- π¨π³
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yong Kang City, Taiwan
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- First Posted Date
- 2010-08-24
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1480
- Registration Number
- NCT01187407
- Locations
- πΈπ°
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roznava, Slovakia
A Study of Olaratumab in Soft Tissue Sarcoma
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 148
- Registration Number
- NCT01185964
- Locations
- πΊπΈ
ImClone Investigational Site, Madison, Wisconsin, United States
A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 4
- Registration Number
- NCT01185548
- Locations
- π¬π§
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 301
- Registration Number
- NCT01185353
- Locations
- πΊπ¦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1056
- Registration Number
- NCT01185340
- Locations
- π¬π§
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chesterfield, United Kingdom
A Study in Migraine Prevention
- Conditions
- Migraine Headache
- Interventions
- Drug: PlaceboDrug: LY2300559
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 87
- Registration Number
- NCT01184508
- Locations
- π΅π·
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico